Enzyme/pH-triggered anticancer drug delivery of chondroitin sulfate modified doxorubicin nanocrystal
Source abstract
Abstract
In this paper, we developed a novel strategy of preparing doxorubicin (DOX) nanocrystal (NC) exerting spherical particles with a diameter of 102 nm, which experienced following coating of chondroitin sulphate derivative (CSOA) shell via electrostatic and hydrophobic interactions. Such multifunctional outerwear resulted in drug nanocapsules with high drug loading content up to 70% and high colloidal stability under physiological conditions. It exhibited accelerated drug release behaviour when dispersing in hyaluronidase (HAase) containing medium or incubated with cancer cells. CSOA/NCs were effectively taken up by cancer cells via CD44 receptor-mediated endocytosis, but were rarely internalised into normal fibroblasts. With the comparison of typical drug-loaded micelles system (DOX/PEG-PCL), CSOA/NCs showed greater inhibition to cancer cells due to the targeted and sensitive drug delivery.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Proteoglycans and glycosaminoglycans research · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, School of Pharmacy, Qingdao University
Department of Clinical laboratory, No.971 Hospital of the People’s Liberation Army Navy
Department of Marketing, Sichuan Kelun Pharmaceutical Co., Ltd
Funding
National Science Foundation of China · Shandong Provincial Natural Science Foundation
References (22)
Show source-provided references
1. 10.1016/j.biomaterials.2015.08.03210.1016/j.biomaterials.2015.08.032 ↗
2. 10.1038/nrd261410.1038/nrd2614 ↗
3. 10.1021/bc200667s10.1021/bc200667s ↗
4. 10.1039/b701327b10.1039/b701327b ↗
5. 10.1039/c2sm25683e10.1039/c2sm25683e ↗
6. 10.1021/nn201370710.1021/nn2013707 ↗
7. 10.1016/j.biomaterials.2016.05.02310.1016/j.biomaterials.2016.05.023 ↗
8. 10.1021/bc400326y10.1021/bc400326y ↗
9. 10.1039/c2cc33214k10.1039/c2cc33214k ↗
10. 10.1039/c1sm06053h10.1039/c1sm06053h ↗
11. 10.1016/j.biomaterials.2009.04.04110.1016/j.biomaterials.2009.04.041 ↗
12. 10.1021/ac000777a10.1021/ac000777a ↗
13. 10.1021/ja504118q10.1021/ja504118q ↗
14. Morelli D, Ménard S, Colnaghi MI, et al. Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Res. 1996;56(9):2082–2085.
15. 10.1021/ja064210910.1021/ja0642109 ↗
16. 10.1039/c3tb20392a10.1039/c3tb20392a ↗
17. 10.1039/C5BM00006H10.1039/C5BM00006H ↗
18. 10.1039/C4CC10226F10.1039/C4CC10226F ↗
19. 10.1016/j.biomaterials.2013.01.10110.1016/j.biomaterials.2013.01.101 ↗
20. 10.1021/acsami.6b1550510.1021/acsami.6b15505 ↗
21. 10.1021/acsami.7b1578010.1021/acsami.7b15780 ↗
22. 10.1002/adma.20130459210.1002/adma.201304592 ↗